A new cross-platform review assessed adverse-event patterns across 18 FDA-approved RNA therapeutics. The analysis found that side-effect profiles depend more on delivery chemistry and administration route than on the RNA modality itself, with most events described as mild in the available reports. The paper also flagged a persistent evidence gap: long-term safety data remain thin relative to the depth of short-term tolerability information. For clinicians and developers, the finding reinforces that risk management for RNA drugs will continue to hinge on the specifics of delivery systems and routes. The review provides a consolidated reference point for ongoing pharmacovigilance discussions while underscoring why extended follow-up and registry-style data collection will remain important for next-generation RNA platforms.